Clinic Revenue Growth and Improved Cash Flow Highlight STIM's Third Quarter
Neuronetics (NASDAQ: STIM) has delivered notable results in its third quarter of 2025, marked by strong clinic revenue growth, significant improvements in operational cash management, and an updated CEO transition timeline. Investors have reason to take notice, as the company’s latest performance points toward progress on both financial stability and clinical impact.
Clinic Revenue Climbs 25% as Acquisition Strategy Pays Off
One of the clearest takeaways from the quarter: STIM’s integration of Greenbrook clinics is generating real revenue momentum. U.S. clinic revenue for Q3 2025 jumped to $21.8 million—up 25% on an adjusted pro forma basis from the prior year. This strength helped total revenue reach $37.3 million, an 11% increase adjusted for acquisitions and a striking 101% jump on a raw comparison to last year.
| Key Revenue Metric | Q3 2025 ($M) | Q3 2024 ($M) | Change (%) |
|---|---|---|---|
| U.S. Clinic Revenue | 21.80 | - | — |
| Total Revenue (adjusted pro forma) | 37.30 | 33.56 | 11.13 |
| Total Revenue (raw) | 37.30 | 18.53 | 101.43 |
This revenue lift largely reflects the strategic impact of the Greenbrook acquisition and a continued focus on efficiency in both clinic and product operations.
Cash Position Strengthens Amid Reduced Losses
STIM’s operational execution is also showing up in its cash management. Cash used in operations for the quarter dropped to just $0.8 million, reflecting continued improvement toward the goal of positive cash flow. The balance sheet was reinforced by a $10 million drawdown from its debt agreement and a $7.8 million equity raise through its at-the-market (ATM) offering. At quarter’s end, total cash and equivalents stood at $34.5 million, up from $19.5 million at the close of 2024.
| Cash Metric | Q3 2025 ($M) | Q4 2024 ($M) |
|---|---|---|
| Total Cash, Equivalents, and Restricted | 34.50 | 19.50 |
| Operating Cash Flow (Q3 2025) | -0.80 | - |
| Net Loss (Q3 2025) | -9.40 | -13.34 (Q3 2024) |
Losses are narrowing as well: Net loss per share was $(0.13), down from $(0.44) in Q3 2024, indicating positive leverage from higher revenues and operational efficiency despite ongoing investment in the clinic network.
Expanded Medicaid Coverage and CEO Succession on the Horizon
The third quarter wasn’t just about financials. Operational milestones include the expansion of New York State Medicaid coverage for NeuroStar’s TMS therapy, broadening access for millions with major depressive disorder. This decision not only cements STIM’s therapy as a leading treatment but also opens a path for potential future payer wins.
Neuronetics also announced a leadership transition plan, with CEO Keith J. Sullivan set to retire in mid-2026. The company is actively searching for a successor and aims to ensure a seamless handoff that won’t disrupt current momentum.
Gross Margins Adjust, Guidance Tightens for Year-End
While gross margin dropped to 45.9% from 75.6% last year—mainly due to the clinic-heavy business mix—the company is managing expenses tightly. Guidance now calls for 2025 revenues between $147 million and $150 million and gross margin between 47% and 49%. Operating expenses are expected in the $100-$105 million range.
| Metric | 2025 Outlook |
|---|---|
| Worldwide Revenue | $147–$150M |
| Gross Margin | 47–49% |
| Operating Expenses | $100–$105M |
Takeaway: Momentum Building Despite Headwinds
Neuronetics’ quarter tells a story of strategic focus paying dividends—clinic revenue growth, cash discipline, and expanded treatment access are real positives, even as device and session sales recalibrate post-acquisition. As the company readies for a leadership change and continued scale, the fundamentals point to resilience and cautious optimism.
With Medicaid coverage expanding and positive cash flow potentially on the horizon, STIM’s path ahead may hold fresh opportunity for those keeping a close watch on innovation and operational turnaround in the mental health technology sector.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI